CURRENT REPORT UNDER SECTION 17 OF THE SECURITIES REGULATION CODE AND SRC RULE 17.2(c) THEREUNDER
1. Date of Report (Date of earliest event reported)
Nov 27, 2017
2. SEC Identification Number
152747
3. BIR Tax Identification No.
000-153-790-000
4. Exact name of issuer as specified in its charter
Ayala Land, Inc.
5. Province, country or other jurisdiction of incorporation
Makati City, Philippines
6. Industry Classification Code(SEC Use Only)
7. Address of principal office
31F Tower One and Exchange Plaza, Ayala Triangle, Ayala Avenue, Makati City, PhilippinesPostal Code1226
8. Issuer's telephone number, including area code
(632) 7506974
9. Former name or former address, if changed since last report
Not Applicable
10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA
Title of Each Class
Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
Common Shares
14,724,947,558
Preferred Shares
13,066,454,759
11. Indicate the item numbers reported herein
Item 9. Other Events
The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.
Ayala Land, Inc.ALI
PSE Disclosure Form 4-13 - Clarification of News Reports References: SRC Rule 17 (SEC Form 17-C) and Section 4.4 of the Revised Disclosure Rules
Subject of the Disclosure
Clarification of News Report
Source
Inquirer.net
Subject of News Report
MVP Group eyes QualiMed
Date of Publication
Nov 27, 2017
Clarification of News Report
We wish to advise that Mercado General Hospital Inc., a joint venture between Whiteknight Holdings, Inc., (a wholly-owned subsidiary of Ayala Land, Inc.) and the Mercado Family, is currently exploring various options intended to strengthen and grow the business of Qualimed.
No definite course of action has been finalized and appropriate disclosures will be submitted to the PSE in a timely manner.